Physician profile
Daniel Lerner
NPI 1700222817
$3,630.22
in general payments reported to CMS, 2019-2025
32 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $495 · 2021: $886 · 2022: $798 · 2023: $389 · 2024: $355 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $785.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $667.59 | 2020-2025 | |
| Lilly USA, LLC | $450.79 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.11 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $196.57 | 2019-2024 | Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $124.37 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $107.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $98.57 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Allergan, INC. | $75.14 | 2019-2020 | |
| Pfizer INC. | $71.90 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $66.58 | 2019-2022 | |
| Amgen INC. | $64.09 | 2024-2025 | Krystexxa, Repatha |
| Medtronic, INC. | $54.76 | 2025 | Percept PC Brainsense |
| Amarin Pharma, INC. | $49.73 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $47.94 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.63 | 2019-2021 | |
| Exact Sciences Corporation | $46.72 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $45.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.51 | 2020-2022 | |
| Eisai INC. | $37.90 | 2021-2024 | |
| Astellas Pharma US INC | $25.21 | 2023 | Veozah |
| Abbott Laboratories | $23.62 | 2025 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $21.82 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.91 | 2024 | Voquezna |
| Adlon Therapeutics L.P. | $19.61 | 2020 | |
| Sumitomo Pharma America, INC. | $19.57 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $18.13 | 2022 | |
| Genentech USA, INC. | $16.09 | 2021 | |
| Mylan Specialty L.P. | $14.99 | 2020 | |
| Cranial Technologies, INC | $12.69 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.66 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.